You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 299 No. 20, May 28, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Similar articles in JAMA
 Topic Collections
 •Statistics and Research Methods
 •Cardiovascular Disease/ Myocardial Infarction
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Adverse Events Associated With Stopping Clopidogrel After Acute Coronary Syndrome—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Kim raises the hypothesis that the clustering of adverse events following stopping clopidogrel is attenuated with longer clopidogrel treatment, specifically among patients taking clopidogrel for longer than 9 months following discharge after acute coronary syndrome. Although length of therapy was not the focus of our investigation, we did include subgroup analysis based on treatment length. Among patients taking clopidogrel for longer than 9 months, 69.6% of total events occurred in the 0- to 90-day interval after stopping clopidogrel, which is higher than the 60.8% reported for the overall medically treated cohort. For the subgroup treated longer than 9 months, the 95% confidence interval (CI) (0.96-3.34) crossed 1, but the interval was wide due to a smaller sample size of patients taking longer courses of clopidogrel, and the magnitude of effect (adjusted incidence rate ratio, 1.79) was similar to the overall cohort, supporting the primary conclusion.

In response . . . [Full Text of this Article]

P. Michael Ho, MD, PhD
michael.ho@uchsc.edu

John S. Rumsfeld, MD, PhD
Denver VA Medical Center
Denver, Colorado



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Adverse Events Associated With Stopping Clopidogrel After Acute Coronary Syndrome
Dae Hyun Kim
JAMA. 2008;299(20):2388-2389.
EXTRACT | FULL TEXT  

Adverse Events Associated With Stopping Clopidogrel After Acute Coronary Syndrome
Sandeep K. Goyal and Sujeeth R. Punnam
JAMA. 2008;299(20):2389.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.